AACR 2025 preview – new preclincal approaches abound
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Ideaya's conjugate journey continues
The synthetic lethality specialist licenses in its second ADC in six months.
Triple meeting 2024 – Zai Lab impresses in small cell
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
Fresh questions over DLL3
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
